Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer
September 21 2016 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that it has granted stock
options to Yvonne Greenstreet, the Company's newly appointed Chief
Operating Officer. The compensation committee of Alnylam's board of
directors approved the grant, effective as of September 19, 2016,
to Dr. Greenstreet of non-qualified stock options to purchase an
aggregate of 150,000 shares of Alnylam's common stock. These
options were granted as an inducement material to Dr. Greenstreet's
entering into employment with the Company in accordance with NASDAQ
Listing Rule 5635(c)(4).
The stock options have a ten-year term and an exercise price
equal to $77.10, the per share closing price of Alnylam's common
stock as reported by NASDAQ on the date of grant. Options to
purchase 125,000 shares will vest over four years, with 25% vesting
on the first anniversary of the grant date and the remainder
vesting ratably at the end of each three-month period thereafter
over the remaining three years, and options to purchase 25,000
shares will vest upon the later of the one year anniversary of the
date of grant and the launch of Alnylam's first internally
developed product, assuming in each case Dr. Greenstreet remains
continuously employed by Alnylam as of such date.
Alnylam is providing this stock option information in accordance
with NASDAQ Listing Rule 5635(c)(4).
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam's pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020"
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company's demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Ionis, Novartis, Roche, Takeda, Merck,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world's top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, New England Journal of Medicine, and The Lancet. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information about Alnylam's pipeline of investigational
RNAi therapeutics, please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160921006385/en/
Alnylam Pharmaceuticals, Inc.(Investors and
Media)Christine Regan Lindenboom, 617-682-4340or(Investors)Josh
Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024